Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
Acta Dermato-Venereologica · 2024
DOI: 10.2340/actadv.v104.34375 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von Akio Tanaka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Patient Reported Outcome Measures, Severity of Illness Index, Drug Therapy, Combination. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly Japan.
Abstract (Originalsprache)
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low- to mid-potency topical corticosteroids on patient-reported outcomes at 16 weeks in Japanese patients with moderate-to-severe atopic dermatitis is evaluated. Eligible patients (n = 286) were randomized 2:2:3 to receive placebo+ topical corticosteroids, 250 mg lebrikizumab every 4 weeks (LEBQ4W+topical corticosteroids, 500 mg loading dose at baseline), or 250 mg lebrikizumab every 2 weeks (LEBQ2W+ topical corticosteroids, 500 mg loading dose at baseline and Week 2) by subcutaneous injection. All PRO endpoints for the study were met; patients in the lebrikizumab in combination with topical corticosteroids groups demonstrated statistically significant and clinically meaningful improvements compared with placebo in combination with topical corticosteroids in Skin Pain NRS, DLQI, POEM, WPAI-AD, and SCORAD scales. Lebrikizumab combined with topical corticosteroids compared with placebo+topical corticosteroids improved patient-reported outcomes in Japanese patients with moderate-to-severe atopic dermatitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Dokkyo Medical University, Dokkyo, Japan.
- Takagi Dermatology Clinic, Japan.
- Shimizu Dermatology Clinic, Japan.
- Osaka Habikino Medical Center, Osaka, Japan.
- Eli Lilly Japan K.K., Kobe, Japan. itakura_hitoe@lilly.com.
Förderung
- Eli Lilly Japan
Zitieren
APA
Tanaka, A., Igawa, K., Takahashi, H., Shimizu, R., Kataoka, Y., Torisu-Itakura, H., Morisaki, Y., Montmayeur, S., & Katoh, N. (2024). Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.34375
Vancouver
Tanaka A, Igawa K, Takahashi H, Shimizu R, Kataoka Y, Torisu-Itakura H, et al. Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis. Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.34375
BibTeX
@article{Tanaka2024,
author = {Tanaka, Akio and Igawa, Ken and Takahashi, Hidetoshi and Shimizu, Ryosuke and Kataoka, Yoko and Torisu-Itakura, Hitoe and Morisaki, Yoji and Montmayeur, Sonia and Katoh, Norito},
title = {Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis},
journal = {Acta Dermato-Venereologica},
year = {2024},
doi = {10.2340/actadv.v104.34375}
}
EUVIMED